Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneron Pharmaceuticals is conducting a Phase 1b study titled ‘Phase 1b Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Patients With Relapsed/Refractory Multiple Myeloma.’ The study aims to evaluate the safety and optimal dosage of linvoseltamab when combined with other cancer treatments for multiple myeloma, a type of blood cancer resistant to standard treatments.
The study tests linvoseltamab, an experimental drug, in combination with various other cancer drugs, including Daratumumab, Carfilzomib, Lenalidomide, and others. Linvoseltamab is administered via intravenous infusion and is being tested for its effectiveness and safety in combination therapies.
This interventional study is non-randomized with a sequential intervention model and no masking, focusing primarily on treatment. The study’s primary goal is to determine the safety and appropriate dosage of linvoseltamab in combination therapies.
The study began on August 17, 2022, and is currently recruiting participants. The last update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
This study could significantly impact Regeneron’s stock performance by potentially introducing a new treatment option for multiple myeloma, enhancing investor sentiment. It also positions Regeneron competitively within the oncology market, particularly against other firms developing similar therapies.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.